Search Results
Results for: SLAUGHTER AND MAY (Save this search)
Number of Results: 63
Shareholders of US Rare Disease Specialist Baxalta Approve USD 32bn Shire Buyout
31 May 2016 - Shareholders of US-based rare disease treatment specialist Baxalta Inc. (NYSE: BXLT) have voted to approve the company's agreed deal to be acquired by Irish drug...

SHAREHOLDERS OF US RARE DISEASE SPECIALIST BAXALTA APPROVE USD 32BN SHIRE BUYOUT
Shareholders of US-based rare disease treatment specialist Baxalta Inc. (NYSE: BXLT) have voted to approve the company's agreed deal to be acquired by Irish drugmaker Shire pl...

RARE DISEASE SPECIALIST BAXALTA POSTS MERGER CONSIDERATION ELECTION RESULTS
US-based rare disease treatment specialist Baxalta Inc. (NYSE: BXLT) has announced the preliminary results of the elections made by its stockholders as to the form of stock conside...

Rare Disease Specialist Baxalta Posts Merger Consideration Election Results
24 May 2016 - US-based rare disease treatment specialist Baxalta Inc. (NYSE: BXLT) has announced the preliminary results of the elections made by its stockholders as to the form of...

US RARE DISEASE SPECIALIST BAXALTA SETS SHAREHOLDER VOTE DATE FOR USD 32BN SHIRE BUYOUT
Shareholders of US-based rare disease treatment specialist Baxalta Inc. (NYSE: BXLT) will vote on 27 May regarding the company's agreed deal to be acquired by Irish drugmaker ...

US Rare Disease Specialist Baxalta Sets Shareholder Vote Date for USD 32bn Shire Buyout
14 April 2016 - Shareholders of US-based rare disease treatment specialist Baxalta Inc. (NYSE: BXLT) will vote on 27 May regarding the company's agreed deal to be acquired by ...

Drugmaker Shire Completes USD 5.9bn Acquisition of Rare Disease Specialist Dyax
25 January 2016 - Irish drugmaker Shire plc (LSE: SHP) (NASDAQ: SHPG) has closed its acquisition of US-based rare disease drug specialist Dyax Corp. (NASDAQ: DYAX), the company sai...

Irish Drugmaker Shire to Buy Rare Disease Specialist Baxalta in USD 32bn Deal
12 January 2016 - The boards of Irish drugmaker Shire plc (LSE: SHP) (NASDAQ: SHPG) and US-based rare disease treatment specialist Baxalta Inc. (NYSE: BXLT) have reached an agreeme...

IRISH DRUGMAKER SHIRE TO BUY RARE DISEASE SPECIALIST BAXALTA IN USD 32BN DEAL
The boards of Irish drugmaker Shire plc (LSE: SHP) (NASDAQ: SHPG) and US-based rare disease treatment specialist Baxalta Inc. (NYSE: BXLT) have reached an agreement under which Shi...

You can compare news articles by clicking on the tick buttons
<  1   2   3   4   5   6   7   >